Change search
ReferencesLink to record
Permanent link

Direct link
PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations
Brussels, Belgium.
Brussels, Belgium.
Vienna, Austria; Moscow, Russia.
Umeå University, Faculty of Medicine, Department of Molecular Biology (Faculty of Medicine). (Hallberg)
Show others and affiliations
2014 (English)In: Oncogene, ISSN 0950-9232, E-ISSN 1476-5594, Vol. 33, no 20, 2568-2576 p.Article in journal (Refereed) Published
Abstract [en]

Activating mutations in the platelet-derived growth factor (PDGF) receptor alpha (PDGFRA) have been described in patients with gastrointestinal stromal tumors or myeloid malignancies associated with hypereosinophilia. These patients respond well to imatinib mesylate, raising the question as to whether patients with a PDGF receptor mutation in other tumor types should receive a tyrosine kinase inhibitor treatment. We characterized 10 novel somatic point mutations in PDGFRA that have been reported in isolated cases of glioblastoma, melanoma, acute myeloid leukemia, peripheral nerve sheath tumors and neuroendocrine carcinoma. The PDGFRA transmembrane domain mutation V536E stimulated Ba/F3 cell growth and signaling via ERK and STAT5 in the absence of ligand. This mutant, identified in glioblastoma, was strongly inhibited by imatinib. Modeling suggested that the mutation modulates the packing of the transmembrane domain helices in the receptor dimer. By contrast, two mutations in highly conserved residues affected the receptor traffic to the cell surface or kinase activity, thereby preventing the response to PDGF. The other mutations had no significant impact on the receptor activity. This functional analysis matched the predictions of SIFT and PolyPhen for only five mutations and these algorithms do not discriminate gain from loss of function. Finally, an E996K variant that had been identified in a melanoma cell line was not expressed in these cells. Altogether, several newly identified PDGFRA mutations do not activate the receptor and may therefore represent passenger mutations. Our results also underline the importance of characterizing novel kinase alterations in cancer patients.

Place, publisher, year, edition, pages
Nature Publishing Group, 2014. Vol. 33, no 20, 2568-2576 p.
Keyword [en]
PDGF receptor, tyrosine kinase inhibitors, glioblastoma, leukemia, GIST
National Category
Cancer and Oncology
URN: urn:nbn:se:umu:diva-81142DOI: 10.1038/onc.2013.218ISI: 000336502700003OAI: diva2:652999
Available from: 2013-10-02 Created: 2013-10-02 Last updated: 2015-09-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Chand, DaminiHallberg, Bengt
By organisation
Department of Molecular Biology (Faculty of Medicine)
In the same journal
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 94 hits
ReferencesLink to record
Permanent link

Direct link